Clinical effect of anti-thrombosis on improved subcutaneous injection of Low Molecular Weight Heparin Calcium
JIN Dapeng1 WANG Wenfeng1 ZHAO Xiujuan2 WANG Haiyan3▲
1.Department of Cardiology, Affiliated Hospital of Chengde Medical College, Hebei Province, Chengde 067000, China;
2.Department of Infection, Langfang People's Hospital of Hebei Province, Hebei Province, Langfang 065000, China;
3.Department of Medical Examination, Affiliated Hospital of Chengde Medical College, Hebei Province, Chengde 067000, China
Abstract：Objective To observe clinical effect and complication of anti-thrombosis on improved subcutaneous injection of Low Molecular Weight Heparin Calcium. Methods 96 patients treated in Outpatient, Affiliated Hospital of Chengde Medical College and need to accept Low Molecular Weight Heparin Calcium antithrombotic therapy from March 2015 to February 2017 were selected as research objects. All patients were grouped according to treatment method. Low Molecular Weight Heparin Calcium modified subcutaneous injection was used in study group (48 cases), conventional injection treatment was applied in control group (48 cases). The platelet aggregation function, blood routine and coagulation function between two groups were observed before and after treatment. Complications, treatment satisfaction between two groups were compared. Results There were no significant difference in PLT, APTT, PAGm-ADP, PT levels between two groups before treatment and after treatment (P > 0.05). PAGm-ADP of two groups after treatment were lower than before treatment, the differences were statistically significant (P ＜ 0.05). The incidence rate of subcutaneous hemorrhage was 6.25% in study group, lower than that in control group (27.08%), the difference was statistically significant (P < 0.05). The incidence rate of induration was 0.00% in study group, lower than that in control group (6.25%), the difference was statistically significant (P < 0.05). Total satisfaction rate of study group was 93.75%, higher than that of control group (81.25%), the difference was statistically significant (P < 0.05). Conclusion The improved subcutaneous injection procedure applied in patients receiving Low Molecular Weight Heparin Calcium antithrombotic therapy can significantly reduce the risk of complication, ensure clinical efficacy, improve treatment satisfaction of patient.
[1] 金歌，张振香，别文倩，等.改良皮下注射流程对低分子肝素钙患者抗血栓效果及并发症的影响[J].中国民康医学，2015（3）：110-111.
[2] 袁艳梅.低分子肝素钙改良注射流程在心肌梗死患者治疗中的应用效果[J].齐鲁护理杂志，2012，18（16）：35-36.
[3] 蔡巧珍.规范低分子肝素钙皮下注射流程的应用与观察[J].中国实用护理杂志，2014，30（z2）：100-101.
[4] Gomaa YA，Garland MJ，McInnes F，et al. Laser-engineered dissolving microneedles for active transdermal delivery of nadroparin calcium [J]. Eur J Pharm Biopharm，2012， 82（2）：299-307.
[5] Yoo MC，Kang CS，Kim YH，et al. A prospective randomized study on the use of nadroparin calcium in the prophylaxis of thromboembolism in Koreanpatients undergoing elective total hip replacement [J]. Int Orthop，1997，21（6）：399-402.
[6] 李季，王妮娜，黎秋月，等.低分子肝素钙应用于老年患者护理体会[J].武警医学，2013，24（5）：449-450.
[7] 于云芳.通心络胶囊联合低分子肝素钙治疗不稳定型心绞痛疗效观察[J].内蒙古中医药，2013，32（34）：12-13.
[8] 刘静华.低分子肝素钙皮下注射治疗慢性阻塞性肺疾病急性加重期合并肺心病疗效观察[J].山东医药，2014（32）：40-42.
[9] 庄芳，刘玉洁，肖玉荣.低分子肝素不同部位的探讨[J].家庭护士，2006，4（1）：33-34.
[10] 赵秀丽，胡大一.抗凝制剂——低分子肝素研究进展[J].心血管病学进展，1998，19（6）：321-323.
[11] Robb DM，Kanji Z. Comparison of two needle size for subcutaneous administration of enoxaparin；effect on size of hematomas and pain on injection [J]. Pharmacotherapy，2002，22（9）：1105-1109.
[12] 区健刚，陈朝进，张丽娜，等.依达拉奉联合低分子肝素治疗进展性脑梗死的临床效果[J].中国当代医药，2016， 23（1）：152-154.
[13] 梁利颜，廖建军.血栓通联合低分子肝素钙在治疗短暂性脑缺血发作中的效果观察[J].中国当代医药，2016， 23（28）：53-55.
[14] 邵娜.低分子肝素钙对慢性肺源性心脏病急性加重期患者肺功能的影响[J].广东医学，2014（11）：1764-1765.
[15] 李章白，钟伟，廖雪梅，等.低分子肝素钙联合灯盏花素治疗老年肺心病疗效分析[J].重庆医学，2014（20）：2587-2588，2591.
[16] 熊明月，刘立强，刘振辉，等.阿仑膦酸钠联合低分子肝素钙治疗老年骨质疏松性骨折的临床效果分析[J].中国生化药物杂志，2014（5）：118-120.
[17] 白丽虹，张燕如.丁苯酞注射液联合低分子肝素钙治疗进展性脑梗死的临床效果[J].中国老年学杂志，2016， 36（10）：2394-2396.
[18] 贾林，黄德清.低分子肝素钙联合椎体成形术治疗老年骨折疏松性椎体压缩性骨折的临床疗效[J].中国生化药物杂志，2017，37（2）：212-215.
[19] 徐学广.替罗非班联合低分子肝素钙对急性非Q波心肌梗死患者的疗效观察[J].中国中西医结合急救杂志，2016，23（4）：429-430.
[20] 陈红，王维，肖彩芝，等.脉通散外敷联合低分子肝素钙治疗老年恶性肿瘤下肢血栓的疗效[J].中国老年学杂志，2016，36（20）：5053-5055.
[21] 熊正方，党小红，李冰，等.低分子肝素钙在多次着床失败患者中的应用[J].实用妇产科杂志，2015，31（8）：614-617.
[22] 傅振会，任波，赵群都，等.低分子肝素钙预防ICU患者静脉血栓栓塞症的临床观察[J].中国药房，2016，27（20）：2838-2841.
[23] 关鹤，于水，杨旭，等.经皮冠状动脉介入术后注射低分子肝素钙管理中品管圈的应用[J].中国组织工程研究，2014（z1）：67-68.
[24] 王涛.血栓弹力图指导下应用低分子肝素钙预防高血压脑出血术后DVT效果观察[J].山东医药，2015（32）：46-47.
[25] 易志刚，郭文安，吴娟，等.银杏叶滴丸联合低分子肝素钙治疗急性冠脉综合征的疗效及对患者心脏功能的影响[J].中国老年学杂志，2016（4）：819-820.
2017, Vol. 14 
京公网安备 11010502046598号